Ninety years of clinical nomenclature has officially ended with the rebranding of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS).
This shift follows a 14-year international collaboration led by clinicians, patients, and researchers to correct a fundamental misunderstanding of the condition. The term "polycystic" has been used since a 1935 paper describing women with polycystic-appearing ovaries, but modern research confirms that no actual cysts are present in the ovaries of affected individuals.
Correcting the Cyst Misconception
What appear to be cysts on an ultrasound are actually tiny follicles containing eggs, which are essential components of female fertility. The term "cyst" carries heavy clinical connotations of large, fluid-filled sacs that may burst or twist, leading to unnecessary patient anxiety and wasted counseling time.
Dr. Anuja Dokras, director of the Penn PMOS Center at Penn Medicine, notes that correcting these inaccuracies has long been a priority for the field. By moving away from the "polycystic" label, clinicians can focus on the actual biological drivers of the syndrome rather than debunking a misnomer.
Beyond Gynecological Symptoms
Historically, the condition was viewed primarily through a gynecological lens due to symptoms like irregular menses, acne, and hair growth. However, multidisciplinary research presented to the National Institutes of Health (NIH) as early as 2012 revealed that the syndrome is far more complex, involving endocrine and metabolic dysfunctions.
The new name, PMOS, explicitly incorporates these "polyendocrine" and "metabolic" aspects. This change aims to address the diagnostic delays that have plagued patients, with surveys showing women often wait between six months and two years to establish a diagnosis, frequently seeing multiple physicians before receiving correct guidance.
This rebranding marks a transition toward a more accurate, holistic diagnostic framework that recognizes the systemic nature of the disorder. The shift to PMOS enables more precise management of the metabolic and endocrine complications that define the syndrome's long-term impact.
Source: PCOS is now PMOS: What went behind renaming the common condition
Domain: scientificamerican.com
Comments load interactively on the live page.